A welcome study from Belgium showing that Penthrox provides substantial time and cost savings per patient in emergency care. The study is based on several assumptions, one of which is government reimbursement. This is why it is so important we get government reimbursement in Germany.
https://www.researchgate.net/profile/Said-Hachimi-Idrissi/publication/350468965_Healthcare_resource_use_and_cost_implications_of_low_dose_methoxyflurane_for_severe_trauma-related_pain_a_qualitative_study/links/6062f83392851cd8ce76693a/Healthcare-resource-use-and-cost-implications-of-low-dose-methoxyflurane-for-severe-trauma-related-pain-a-qualitative-study.pdf
Another Positive Study, page-3
-
- There are more pages in this discussion • 189 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MVP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
47.5¢ |
Change
0.010(2.15%) |
Mkt cap ! $53.51M | |||
| Open | High | Low | Value | Volume |
| 46.5¢ | 48.0¢ | 46.5¢ | $42.73K | 90.23K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 26916 | 47.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 48.5¢ | 4750 | 2 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| MVP (ASX) Chart |